Fox Run Management L.L.C. Acquires New Holdings in Vera Therapeutics, Inc. $VERA

Key Points

• Fox Run Management L.L.C. has acquired 19,597 shares of Vera Therapeutics, Inc., valued at approximately $471,000, as indicated in their recent SEC filing.
• Insider Patrick G. Enright purchased 40,607 shares of Vera Therapeutics at an average price of $22.35, totaling around $907,566, increasing his ownership by 1.14%.
• Vera Therapeutics reported a loss of ($1.20) EPS in its latest earnings, missing consensus estimates, with analysts projecting an average of -2.89 EPS for the current year.

Fox Run Management L.L.C. purchased a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 19,597 shares of the company's stock, valued at approximately $471,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in Vera Therapeutics during the 4th quarter worth approximately $56,000. Summit Investment Advisors Inc. increased its stake in shares of Vera Therapeutics by 16.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after buying an additional 639 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Vera Therapeutics in the fourth quarter worth $264,000. GAMMA Investing LLC raised its holdings in Vera Therapeutics by 1,779.1% in the first quarter. GAMMA Investing LLC now owns 8,287 shares of the company's stock valued at $199,000 after acquiring an additional 7,846 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Vera Therapeutics by 19.7% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,533 shares of the company's stock worth $229,000 after acquiring an additional 1,572 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Performance

Vera Therapeutics stock traded down $0.04 during mid-day trading on Friday, reaching $22.57. The company's stock had a trading volume of 2,043,455 shares, compared to its average volume of 1,616,418. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -6.30 and a beta of 1.17. The business has a 50 day moving average price of $22.11 and a 200-day moving average price of $23.97. The company has a current ratio of 17.03, a quick ratio of 17.03 and a debt-to-equity ratio of 0.16. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same period in the previous year, the business earned ($0.62) EPS. Sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Ratings Changes

VERA has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Wolfe Research restated a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. HC Wainwright reiterated a "buy" rating and issued a $85.00 target price (up previously from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Finally, Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Vera Therapeutics has an average rating of "Moderate Buy" and an average target price of $63.00.

Insider Activity

In related news, Director Patrick G. Enright acquired 40,607 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, June 24th. The stock was acquired at an average price of $22.35 per share, for a total transaction of $907,566.45. Following the transaction, the director directly owned 3,596,593 shares of the company's stock, valued at $80,383,853.55. This trade represents a 1.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 16.30% of the company's stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.